Radiopharm Theranostics Limited (ASX:RAD)
Australia
· Delayed Price · Currency is AUD | Market Cap | 54.39M |
| Revenue (ttm) | 330.63K |
| Net Income (ttm) | -43.00M |
| Shares Out | 2.36B |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,777 |
| Average Volume | 2,291,805 |
| Open | 0.0230 |
| Previous Close | 0.0230 |
| Day's Range | 0.0230 - 0.0230 |
| 52-Week Range | 0.0190 - 0.0480 |
| Beta | 0.84 |
| RSI | 44.40 |
| Earnings Date | May 29, 2025 |
About Radiopharm Theranostics
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a... [Read more]
Financial Performance
In 2024, Radiopharm Theranostics's revenue was 1.96 million, a decrease of -68.46% compared to the previous year's 6.21 million. Losses were -47.95 million, 38.5% more than in 2023.
Financial StatementsNews
Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page ....